Physio-Chemistry Department, Centre d'Immunologie Pierre-Fabre, Saint julien en Genevois, France.
MAbs. 2011 Mar-Apr;3(2):111-32. doi: 10.4161/mabs.3.2.14788. Epub 2011 Mar 1.
The 6th European Antibody Congress (EAC), organized by Terrapinn Ltd., was held in Geneva, Switzerland, which was also the location of the 4th and 5th EAC. As was the case in 2008 and 2009, the EAC was again the largest antibody congress held in Europe, drawing nearly 250 delegates in 2010. Numerous pharmaceutical and biopharmaceutical companies active in the field of therapeutic antibody development were represented, as were start-up and academic organizations and representatives from the US Food and Drug Administration FDA. The global trends in antibody research and development were discussed, including success stories of recent marketing authorizations of golimumab (Simponi®) and canakinumab (Ilaris®) by Johnson & Johnson and Novartis, respectively, updates on antibodies in late clinical development (obinutuzumab/GA101, farletuzumab/MORAb-003 and itolizumab/T1 h, by Glycart/Roche, Morphotek and Biocon, respectively) and success rates for this fast-expanding class of therapeutics (Tufts Center for the Study of Drug Development). Case studies covering clinical progress of girentuximab (Wilex), evaluation of panobacumab (Kenta Biotech), characterization of therapeutic antibody candidates by protein microarrays (Protagen), antibody-drug conjugates (sanofi-aventis, ImmunoGen, Seattle Genetics, Wyeth/Pfizer), radio-immunoconjugates (Bayer Schering Pharma, Université de Nantes) and new scaffolds (Ablynx, AdAlta, Domantis/GlaxoSmithKline, Fresenius, Molecular Partners, Pieris, Scil Proteins, Pfizer, University of Zurich) were presented. Major antibody structural improvements were showcased, including the latest selection engineering of the best isotypes (Abbott, Pfizer, Pierre Fabre), hinge domain (Pierre Fabre), dual antibodies (Abbott), IgG-like bispecific antibodies (Biogen Idec), antibody epitope mapping case studies (Eli Lilly), insights in FcγRII receptor (University of Cambridge), as well as novel tools for antibody fragmentation (Genovis). Improvements of antibody druggability (Abbott, Bayer, Pierre Fabre, Merrimack, Pfizer), enhancing IgG pharmacokinetics (Abbott, Chugai), progress in manufacturing (Genmab, Icosagen Cell Factory, Lonza, Pierre Fabre) and the development of biosimilar antibodies (Biocon, Sandoz, Triskel) were also discussed. Last but not least, identification of monoclonal antibodies (mAbs) against new therapeutic targets (Genentech, Genmab, Imclone/Lilly, Vaccinex) including Notch, cMet, TGFbRII, SEMA4D, novel development in immunotherapy and prophylaxis against influenza (Crucell), anti-tumor activity of immunostimulatory antibodies (MedImmune/Astra Zeneca) and translations to clinical studies including immunogenicity issues (Amgen, Novartis, University of Debrecen) were presented.
第六届欧洲抗体大会（EAC）由 Terrapinn Ltd. 组织，在瑞士日内瓦举行，这也是第四届和第五届 EAC 的举办地。与 2008 年和 2009 年一样，EAC 是欧洲举办的最大的抗体会议，2010 年吸引了近 250 名代表。许多活跃在治疗性抗体开发领域的制药和生物制药公司都有代表参加，初创企业和学术组织以及美国食品和药物管理局（FDA）的代表也参加了会议。会议讨论了抗体研究和开发的全球趋势，包括强生公司和诺华公司最近成功获得戈利木单抗（Simponi®）和卡那奴单抗（Ilaris®）的营销许可的成功案例，处于后期临床开发阶段的抗体的最新进展（奥滨尤妥珠单抗/GA101、farletuzumab/MORAb-003 和 itolizumab/T1h，分别由 Glycart/Roche、Morphotek 和 Biocon 开发），以及这个快速发展的治疗类药物的成功率（塔夫茨药物开发研究中心）。会议还介绍了涵盖吉立替尼（Wilex）临床进展的案例研究、泛单抗（Kenta Biotech）的评估、蛋白质微阵列（Protagen）对治疗性抗体候选物的表征、抗体药物偶联物（赛诺菲-安万特、ImmunoGen、西雅图遗传学、惠氏/辉瑞）、放射免疫偶联物（拜耳先灵医药、南特大学）和新型支架（Ablynx、AdAlta、Domantis/葛兰素史克、法液空、分子伙伴、Pieris、Scil 蛋白、辉瑞、苏黎世大学）。介绍了主要的抗体结构改进，包括最新的最佳同型选择工程（雅培、辉瑞、皮埃尔法伯）、铰链区（皮埃尔法伯）、双抗体（雅培）、IgG 样双特异性抗体（百健艾迪）、抗体表位作图案例研究（礼来）、FcγRII 受体的见解（剑桥大学），以及抗体片段化的新工具（Genovis）。还讨论了抗体成药性的改进（雅培、拜耳、皮埃尔法伯、Merrimack、辉瑞）、增强 IgG 药代动力学（雅培、中外制药）、制造方面的进展（Genmab、Icosagen Cell Factory、龙沙、皮埃尔法伯）和生物类似抗体的开发（Biocon、山德士、Triskel）。最后但同样重要的是，介绍了针对新治疗靶点的单克隆抗体（mAbs）的鉴定（基因泰克、基因泰克、Imclone/Lilly、Vaccinex），包括 Notch、cMet、TGFbRII、SEMA4D、流感免疫治疗和预防的新进展（Crucell）、免疫刺激抗体的抗肿瘤活性（MedImmune/阿斯利康）以及包括免疫原性问题在内的临床研究转化（安进、诺华、德布勒森大学）。
